ArticleSignal transduction and targeted therapy2020
COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm.
Article in Signal transduction and targeted therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 141 citations in OpenAlex.
- PCSK9 in critical illness - It's not all about lipids.Annals of clinical biochemistry · 2026Review
- SREBP2 promotes macrophage alternative activation and allergic airway inflammation independent of cholesterol biosynthesis.Cell death & disease · 2026Article
- Review
- Cleaved SREBP-2 C-terminal fragment noncanonically drives interleukin-1 receptor-associated kinase 1-dependent apoptosis.Signal transduction and targeted therapy · 2026Article
- Interplay Between NLRP3 Activation by DENV-2 and Autophagy and Its Impact on Lipid Metabolism in HMEC-1 Cells.Pathogens (Basel, Switzerland) · 2025Article
- SREBP2-dependent lipid droplet formation enhances viral replication and deteriorates lung injury in mice following IAV infection.Emerging microbes & infections · 2025Article
- Profiles of PCSK9, SREBP-2, and histopathology in COVID-19 and non-COVID-19 critical illness.BMC infectious diseases · 2025Article
- Proteomics and Metabolomics Profiles of Unvaccinated Nonagenarian Patients with Severe SARS-CoV-2 Infection.Journal of proteome research · 2025Article
- Influenza virus infection reprograms cholesterol biosynthesis to facilitate virus replication by the TAK1-RORγ axis.PLoS pathogens · 2025Article
- ICOS regulates IL-10 production in group 2 innate lymphoid cells via cholesterol and cortisol biosynthesis.The Journal of clinical investigation · 2025Article
- Membrane protein CRISPR screen identifies RPSA as an essential host factor for porcine epidemic diarrhea virus replication.Journal of virology · 2025Article
- Structural basis for substrate selectivity by site-one protease revealed by studies with a small-molecule inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Serum HDL and their subfractions are impaired in multisystem inflammatory syndrome in children (MIS-C).Journal of translational medicine · 2025Article
- c-Met inhibitor NVP-BVU972 induces antiviral protection and suppresses NF-κB-mediated inflammation.Frontiers in immunology · 2025Article
- Dyslipidemia in severe fever with thrombocytopenia syndrome patients: A retrospective cohort study.PLoS neglected tropical diseases · 2024Article
- Cholesterol and Cholesterol-Lowering Medications in COVID-19-An Unresolved Matter.International journal of molecular sciences · 2024Review
- Post-Acute Sequelae and Mitochondrial Aberration in SARS-CoV-2 Infection.International journal of molecular sciences · 2024Review
- Hyperactivation of SREBP induces pannexin-1-dependent lytic cell death.Journal of lipid research · 2024Article
- The TOX-RAGE axis mediates inflammatory activation and lung injury in severe pulmonary infectious diseases.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The prognostic significance of insulin resistance in COVID-19: a review.Journal of diabetes and metabolic disorders · 2024Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
Sterol regulatory element binding protein-2 (SREBP-2) is activated by cytokines or pathogen, such as virus or bacteria, but its association with diminished cholesterol levels in COVID-19 patients is unknown. Here, we evaluated SREBP-2 activation in peripheral blood mononuclear cells of COVID-19 patients and verified the function of SREBP-2 in COVID-19. Intriguingly, we report the first observation of SREBP-2 C-terminal fragment in COVID-19 patients' blood and propose SREBP-2 C-terminal fragment as an indicator for determining severity. We confirmed that SREBP-2-induced cholesterol biosynthesis was suppressed by Sestrin-1 and PCSK9 expression, while the SREBP-2-induced inflammatory responses was upregulated in COVID-19 ICU patients. Using an infectious disease mouse model, inhibitors of SREBP-2 and NF-κB suppressed cytokine storms caused by viral infection and prevented pulmonary damages. These results collectively suggest that SREBP-2 can serve as an indicator for severity diagnosis and therapeutic target for preventing cytokine storm and lung damage in severe COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.